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Epigenetics refers to all heritable changes, which 
are not dependent on alterations of DNA primary 
structure [1]. Among them, histone post-translational 
modifications (HPTMs) play a crucial role in regulating 
gene expression. Histones are core chromatin components, 
organized in cylindrical structures. The nucleosome is the 
fundamental chromatin unit: it is made of appreciatively 
150 bp. DNA wrapped around a cylindrical histone 
core [2]. Histone N-terminal tails protrude from this 
compact structure, and may be modified by several 
HPTMs (acetylation, methylation, phosphorylation…). 
Each modification occurs on a specific residue, and is 
mediated by an enzymatic complex. Since HPTMs dictate 
DNA-chromatin binding and gene activity, it has been 
proposed that a complex histone code orchestrates gene 
expression in mammalian cells [2]. HPTMs have been 
shown to control several developmental processes, and 
are deregulated in many human diseases, including cancer. 
Among HPTMs, methylation is particularly interesting, 
because it can activate or silence gene expression, 
depending on target amino acidic residue. For example, 
histone H3-Lys27 trimethylation, mediated by Polycomb 
member EZH2, is known to silence gene expression; while 
histone H3-Lys36 dimethylation, mediated by NSD1, is 
an activating mark [3]. HPTMs appear to be crucial for 
stem cell self-renewal and tissue specification, and may be 
involved in some developmental diseases [2].
Inactivating NSD1 gerrmline mutations have 
been shown to occur in individuals affected by Sotos 
syndrome (SS), characterized by accelerated pre- and 
post-natal growth, macrocephaly, advanced bone age and 
developmental delay [4]. Interestingly, NSD1 mutations 
are rare in similar but less frequent overgrowth conditions, 
including Weaver syndrome (WS). WS shares with SS the 
above mentioned hallmarks. However, individuals with SS 
are less likely to show increased birth weight than patients 
affected by WS, and in childhood tend to be taller and 
thinner [5]. Moreover, facial appearance is different in 
these two syndromes. Two recent papers [6, 7] found a 
possible genetic explanation for these slight and apparently 
questionable clinical differences. Both studies started 
from a whole-genome screening of possible mutations in 
a small number of subjects with WS. Surprisingly, both 
studies found that EZH2 gene was frequently mutated 
in those patients. The study published in the December 
issue of Oncotarget also confirmed the presence of EZH2 
mutations in a larger set of patients affected by overgrowth 
syndrome [7]. Most mutations appear to occur de novo and 
are predicted to inactivate the gene, through deletion or 
alteration of the catalytic domain. Thus, EZH2 alterations 
may somehow cause WS. Due to the role of EZH2 in 
maintaining stem cell self-renewal and delaying tissue 
specification [2], it is conceivable that inactivation of this 
gene triggers the accelerated bone maturation observed in 
WS. Intriguingly, EZH2 is also involved in brain stem cell 
differentiation [2], and most WS patients display learning 
disabilities. Thus, the putative relationship between 
histone methylation and brain development may open the 
way to a new perspective for epigenetic research. 
It is less clear whether EZH2 mutations predispose 
for neoplasia. Indeed, 2 of 19 patients with overgrowth 
syndrome and EZH2 mutation developed a tumor. One 
of them developed neuroblastoma and lymphoma. Both 
neoplasms have been previously associated with EZH2 
hyperactivation [8, 9]. Interestingly, this patient displayed 
a missense mutation in the catalytic domain, which may 
not simply inactivate protein function. For example, a 
coordinated activity of wild-type and mutant EZH2 was 
shown to drive histone H3-Lys27 trimethylation in human 
B-cell Lymphomas [9]. Another obscure issue is why 
mutations in two counteracting epigenetic effectors (NDS1 
and EZH2) cause very similar syndromes.
Future studies should shed new light on the complex 
relationship between HPTMs and human development. 
In particular, the molecular function of EZH2 and NSD1 
in bone development  should be addressed. Moreover, 
histone methylation and demethylation may be modulated 
by novel small molecule inhibitors[10, 11], which may 
pave the way to a therapeutic approach for those rare 
syndromes. 
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